Elsevier

The Lancet

Volume 344, Issue 8926, 24 September 1994, Pages 856-857
The Lancet

Short reports
Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine

https://doi.org/10.1016/S0140-6736(94)92829-0Get rights and content

Abstract

Natural interleukin-2 at low dose has been reported to overcome the non-responsiveness of patients with chronic uraemia to hepatitis B vaccine. Therefore, we revaccinated 52 previous such non-responders (24 on maintenance dialysis) with 20 μg of recombinant preS2–containing hepatitis B vaccine with human recombinat interleukin-2 (1 MU) or placebo (randomly allocated). Seroconversion rates (74 vs 80%, respectively) and proportion of patients who elicited anti-HBs titres of 10 m/U/mL or more (56 vs 68%) were similar in both groups. Our rsults do not confirm local injection of interleukin-2 as an effective imunoadjuvant to hepatitis B vaccine in uraemic patients. Lancet 1994; 344: 856–57

References (11)

There are more references available in the full text version of this article.

Cited by (67)

  • Hepatitis B virus vaccine in chronic kidney disease: Improved immunogenicity by adjuvants? A meta-analysis of randomized trials

    2012, Vaccine
    Citation Excerpt :

    A complete list of the 133 reports reviewed is available from the authors on request. A total of nine reports giving information on ten RTCs were included in our meta-analysis [19–27]. There was a 100% concordance between reviewers with respect to final inclusion and exclusion of studies reviewed based on the predefined inclusion and exclusion criteria.

  • Enhancement of the immune responses to vaccination against foot-and-mouth disease in mice by oral administration of an extract made from Rhizoma Atractylodis Macrocephalae (RAM)

    2009, Vaccine
    Citation Excerpt :

    Therefore, there is a need to improve currently available vaccines in order to effectively protect humans and animals from infection. Strategies to improve the immune response to vaccination have included the use of higher vaccine dose or increasing number of doses, use of different route of administration (e.g., intradermal versus intramuscular administration), accelerating dosing schedule and use of adjuvants such as antigen delivery systems and various immunomodulators [8–16] There is growing evidence that medicinal herbs and the ingredients enhance the immune response to vaccines direct against infectious agents [17,18]. Medicinal herbs have a variety of effects on immune responses and co-administration with herbal extracts has been shown to increase the antibody response and to enhance the proliferative response of T cells [19,20].

  • Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: A meta-analysis

    2007, Vaccine
    Citation Excerpt :

    Actually, the antibody response is lower in patients with diabetes mellitus, renal failure and chronic liver disease, as well as in immunocompromised patients, such as those infected with HIV. Strategies to improve the HBV vaccine response rate have included the use of higher vaccine dose or increasing number of doses, use of different route of administration (e.g., intradermal versus intramuscular administration), accelerating dosing schedule and use of adjuvants such as antigen delivery systems and various immunomodulators [3,9–17]. There is growing evidence that granulocyte macrophage colony-stimulating factor (GM-CSF) enhances the immune response to vaccines direct against both infectious agents and various cancers [16,17].

  • The use of vaccines in adult patients with renal disease

    2005, American Journal of Kidney Diseases
View all citing articles on Scopus
View full text